epigallocatechin gallate has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R | 1 |
| Akber Ansari, S; Ali, R; Badshah, SL; Bari, A; Jamal, SB; Majid Mahmood, H; Shahid, F; Sohaib, M; Ullah, R | 1 |
| Ho, WZ; Li, JL; Wang, X; Wang, YZ; Zhang, T | 1 |
| Abdelaziz, AI; El Sobky, SA; El-Ekiaby, N; El-Sayed, M; Elemam, NM; Esmat, G; Hamza, MT; Mekky, RY; Youness, RA | 1 |
| Abdelaziz, AI; El-Ekiaby, NM; El-Sayed, M; Elemam, NM; Esmat, G; Hamza, MT; Mekky, RY | 1 |
| Burton, DR; Douglas, D; Egli, A; Forester, S; Houghton, M; Humar, A; Kneteman, N; Lambert, J; Law, J; Law, M; Lund, G; O'Shea, D; Tyrrell, DL | 1 |
| Khan, H; Murad, S; Neyts, J; Paeshuyse, J | 1 |
| Ciesek, S; Colpitts, CC; Friesland, M; Manns, MP; Meuleman, P; Ott, M; Pietschmann, T; Schang, LM; Steinmann, E; Steinmann, J; von Hahn, T; Wedemeyer, H | 1 |
| Albecka, A; Belouzard, S; Calland, N; Descamps, V; Dubuisson, J; Duverlie, G; Hober, D; Rouillé, Y; Séron, K; Wychowski, C | 1 |
| Jo, SK; Kim, SE; Roh, C | 1 |
| Fukazawa, H; Murakami, Y; Suzuki, T; Wakita, T | 1 |
1 trial(s) available for epigallocatechin gallate and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Novel combined single dose anti-hepatitis C therapy: a pilot study.
Topics: Adult; Antiviral Agents; Catechin; Female; Genotype; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Ribavirin; Sofosbuvir | 2021 |
10 other study(ies) available for epigallocatechin gallate and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Identification of Potential HCV Inhibitors Based on the Interaction of Epigallocatechin-3-Gallate with Viral Envelope Proteins.
Topics: Antiviral Agents; Catechin; Hepacivirus; Hepatitis C; Humans; Ligands; Molecular Docking Simulation; Polyphenols; Tea; Viral Envelope; Viral Envelope Proteins; Virus Internalization | 2021 |
(-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes.
Topics: Antiviral Agents; Catechin; Cell Line, Tumor; DEAD Box Protein 58; Enzyme-Linked Immunosorbent Assay; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Immunity, Innate; Interferon-gamma; Interferon-Stimulated Gene Factor 3, gamma Subunit; Poly I-C; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Signal Transduction; Toll-Like Receptor 3; Viral Core Proteins; Virus Replication | 2017 |
Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models.
Topics: 3' Untranslated Regions; Case-Control Studies; Catechin; Cell Line; Computer Simulation; Gene Expression Profiling; Gene Expression Regulation; Hepacivirus; Hepatitis C; Humans; MicroRNAs; Tetraspanin 28; Virus Internalization | 2019 |
Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor.
Topics: Catechin; Computational Biology; Flow Cytometry; Hepacivirus; Hepatitis C; Humans; Liver; Liver Transplantation; MicroRNAs; Reverse Transcriptase Polymerase Chain Reaction; Tetraspanin 28; Up-Regulation | 2015 |
Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Broadly Neutralizing Antibodies; Catechin; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis Viruses; Humans; Liver; Mice, SCID; Time Factors | 2016 |
Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.
Topics: Antiviral Agents; Catechin; Food Additives; Genotype; Hepacivirus; Hepatitis C; Humans; Nitro Compounds; Prevalence; Silybin; Silymarin; Thiazoles; Virus Replication | 2016 |
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
Topics: Catechin; Cell Line, Tumor; Cells, Cultured; Hepacivirus; Hepatitis C; Humans; Tea; Virus Attachment; Virus Internalization | 2011 |
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Topics: Animals; Antiviral Agents; Catechin; Cattle; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Kidney; Lipid Metabolism; Models, Animal; Plant Extracts; Tea; Vero Cells; Virus Internalization; Virus Replication | 2012 |
Label free inhibitor screening of hepatitis C virus (HCV) NS5B viral protein using RNA oligonucleotide.
Topics: Antiviral Agents; Aptamers, Nucleotide; Biotin; Catechin; Computer Systems; Hepacivirus; Hepatitis C; Humans; Streptavidin; Viral Nonstructural Proteins | 2011 |
A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the hepatitis C virus.
Topics: Antiviral Agents; Benzoflavones; Camellia sinensis; Catechin; Cell Line, Tumor; Cyclosporine; Drug Evaluation, Preclinical; Flavones; Hepacivirus; Hepatitis C; Humans; Phytotherapy; Reproducibility of Results; Tamoxifen | 2012 |